Lilly's monoclonal antibody therapy bamlanivimab has been granted Emergency Use Authorization in the US for recently diagnosed, mild-to-moderate COVID-19 in high-risk patients.
The decision by the US Food and Drug Administration makes Lilly the first to bring an antibody therapy to patients,...







